Click here for NICC Library Webpage
Login
My List - 0
Help
Search
My Account
ID Information
Calmar New Materials
Peosta New Materials
Advanced
Alphabetical
Basic
History
Search:
General Keyword
Title Keyword
Author Keyword
Subject Keyword
ISBN/ISSN Exact Match
ISBN/ISSN Browse
Serial Title Browse
Title Alphabetical
Subject Alphabetical
Author Alphabetical
Alphabetical Series
Barcode
Bib No.
Journal/Newspaper Title Browse
Series Keyword
Refine Search
> You're searching:
Northeast Iowa Community College
Item Information
Holdings
More by this author
Carreyrou, John, author.
Subjects
Holmes, Elizabeth, 1984-
Theranos (Firm) -- History.
Hematologic equipment industry -- United States.
New business enterprises -- Corrupt practices -- United States -- Cases.
Securities fraud -- United States. -- Cases.
Browse Catalog
by author:
Carreyrou, John, author.
by title:
Bad blood : secrets ...
MARC Display
Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou.
by
Carreyrou, John, author.
New York : Alfred A. Knopf, 2018
Description:
x, 339 pages ; 25 cm
Edition:
First edition.
Contents:
A purposeful life -- The gluebot -- Apple envy -- Goodbye East Paly -- The childhood neighbor -- Sunny -- Dr. J -- The miniLab -- The wellness play -- "Who is LTC Shoemaker?" -- Lighting a Fuisz -- Ian Gibbons -- Chiat\Day -- Going live -- Unicorn -- The grandson -- Fame -- The Hippocratic Oath -- The tip -- The ambush -- Trade secrets -- La mattanza -- Damage control -- The empress has no clothes -- Epilogue.
Summary:
"In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When John Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley." -- Publisher's description
The full inside story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. A riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley.
Copy/Holding information
Location
Collection
Call No.
Copy
Status
Calmar Campus Library
Circulation Stacks (Calmar)
338.7 Car
2018
Checked In
Add Copy to MyList
Format:
HTML
Plain text
Delimited
Subject:
Email to:
Horizon Information Portal 3.25_9807
© 2001-2013
SirsiDynix
All rights reserved.